NanoBio Corporation to Collaborate in Research Effort for Respiratory Syncytial Virus Vaccine With Merck & Co., Inc.
Published: Dec 08, 2011
ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced a preclinical collaboration with a subsidiary of Merck & Co., Inc., focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat® adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat® adjuvant for development of a commercial RSV vaccine.